Status:
COMPLETED
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Multiple Sclerosis
NMO Spectrum Disorder
Eligibility:
All Genders
Brief Summary
The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being i...
Detailed Description
There are currently no data on the consequences of coronavirus infection in patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder. Numerous questions have emerged regar...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patient with MS or NMO
- at least one of the following four criteria:
- COVID + biologically confirmed
- Typical ground glass opacity on thoracic CT-scan in epidemic areas
- Anosmia or ageusia of sudden onset in the absence of rhinitis or nasal obstruction
- Typical symptoms (triad associating cough, fever, asthenia) in epidemic zone
- Non opposition of the patient to the use of these data or non opposition of the confidential counselor / parent / relative (if the patient is unable to give his non-opposition, with collection as soon as possible of the non opposition of the patient) or non opposition of the 2 holders of parental authority (for minor patients)
- Non-inclusion criteria
- \- Patient under guardianship or safety measure
Exclusion
Key Trial Info
Start Date :
April 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
2465 Patients enrolled
Trial Details
Trial ID
NCT04355611
Start Date
April 17 2020
End Date
June 30 2022
Last Update
February 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Pitié Salpétrière
Paris, France, 75013